<?xml version='1.0' encoding='utf-8'?>
<document id="28844584"><sentence text="Consistency of psychotropic drug-drug interactions listed in drug monographs." /><sentence text="With an increasing prevalence of psychotropic polypharmacy, clinicians depend on drug-drug interaction (DDI) references to ensure safe regimens, but the consistency of such information is frequently questioned" /><sentence text="" /><sentence text="To evaluate the consistency of psychotropic DDIs documented in Clinical Pharmacology (CP), Micromedex (MM), and Lexicomp (LC) and summarize consistent psychotropic DDIs" /><sentence text="" /><sentence text="In May 2016, we extracted severe or major psychotropic DDIs for 102 psychotropic drugs, including central nervous system (CNS) stimulants, antidepressants, an antimanic agent (lithium), antipsychotics, anticonvulsants, and anxiolytics-sedatives-hypnotics from CP, MM, and LC" /><sentence text=" We then summarized the psychotropic DDIs that were included in all 3 references and with evidence quality of &quot;excellent&quot; or &quot;good&quot; based on MM" /><sentence text="" /><sentence text="We identified 1496, 938, and 1006 unique severe or major psychotropic DDIs from CP, MM, and LC, respectively" /><sentence text=" Common adverse effects related to psychotropic DDIs include increased or decreased effectiveness, CNS depression, neurotoxicity, QT prolongation, serotonin syndrome, and multiple adverse effects"><entity charOffset="147-156" id="DDI-PubMed.28844584.s10.e0" text="serotonin" /></sentence><sentence text=" Among these interactions, only 371 psychotropic DDIs were documented in all 3 references, 59 of which had &quot;excellent&quot; or &quot;good&quot; quality of evidence based on MM" /><sentence text="" /><sentence text="The consistency of psychotropic DDI documentation across CP, MM, and LC is poor" /><sentence text=" DDI documentations need standards that would encourage consistency among drug information references" /><sentence text=" The list of the 59 DDIs may be useful in the assessment of psychotropic polypharmacy and highlighting DDI alerts in clinical practice" /><sentence text="" /></document>